Partially humanized, chimeric recombinant monoclonal antibody to HIV-1 p24 (clone 5)

Catalogue #

C-851-100

Name

Partially humanized, chimeric recombinant monoclonal antibody to HIV-1 p24 (clone 5)

Description

Antibody is derived from mouse anti-HIV-1 (HAN subtype) p17/24 monoclonal antibody clone 5 expressing mouse hybridoma culture. cDNA of antibody variable regions were isolated and cloned into the human IgG1 constant region-containing antibody expression vector. Partially humanized, chimeric antibody was expressed by QMCF CHOEBNALT85 cell line. Antibody is used for high-specific efficient detection of soluble or membrane-bound proteins fused with 05-001 epitope-tag sequence.

Target

HIV-1 p24

Target Description

Recombinant p24 protein of HIV-1 HAN consensus produced in E. coli

Clonality

Human monoclonal

Clone

5

Class

hIgG1

Reactivity

Reacts with HIV-1 p24 subtype B, C and A. Mapped to 48-62 (TPQDLNTMLNTVGGH)

Application

ELISA, WB, IF

Protocol

ELISA:

0.16 to 0.3 µg/ml

WB:

1 µg/ml

IF:

1 to 10 µg/ml

Purification

Protein A affinity chromatography followed by gel filtration

Buffer

PBS pH 7.4, 50% glycerol

Related Products

Mouse anti-HIV 1 p24 monoclonal antibody clone 5, cat# A2-851-100.

Shipping

Shipping in ambient conditions.

Storage

Store at -20 °C to -70 °C. Avoid multiple freeze-thaw cycles.

Background

HIV-1 p24 is a crucial protein component of the human immunodeficiency virus type 1 (HIV-1), the virus responsible for causing acquired immunodeficiency syndrome (AIDS). It is encoded by the Gag gene and serves as a fundamental building block for the viral core capsid. Due to its consistent presence in HIV-1, p24 has become an essential diagnostic marker for detecting HIV infection. Diagnostic tests, such as enzyme-linked immunosorbent assays (ELISAs) and rapid antibody tests, are specifically designed to detect antibodies that the patient's immune system produces in response to HIV-1 p24 protein. This antibody detection is a crucial step in diagnosing HIV infection. However, in the early stages of HIV infection, when the patient's immune response is still developing and antibodies may not be present in sufficient quantities for detection, the direct detection of p24 antigen in the bloodstream becomes exceptionally valuable. The current recommendations advocate the use of antibody-antigen assays, which can detect p24 and the antibody response to the virus. These assays are favoured for HIV screening due to their capability to shorten the time between infection and a positive HIV test result to less than one month.